Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer

Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer

Francisco Quiñonero,1,2,&ast; Belén Parra-Torrejón,3,&ast; Gloria B Ramírez-Rodríguez,3 Victor Garcés,3 José M Delgado-López,3 Cristina Jiménez-Luna,1,2,4 Gloria Perazzoli,1,2,4 Consolación Melguizo,1,2,4 Jose Prados,1,2,4 Raul Ortíz1,2,4 1Institute of Biopathology and Regenerative Medicine...

Full description

Bibliographic Details
Main Authors:	Quiñonero F, Parra-Torrejón B, Ramírez-Rodríguez GB, Garcés V, Delgado-López JM, Jiménez-Luna C, Perazzoli G, Melguizo C, Prados J, Ortíz R
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-09-01
Series:	International Journal of Nanomedicine
Subjects:	nanomedicine calcium phosphate nanocarriers olaparib ascorbic acid synergistic effect pancreatic cancer
Online Access:	https://www.dovepress.com/combining-olaparib-and-ascorbic-acid-on-nanoparticles-to-enhance-the-d-peer-reviewed-fulltext-article-IJN

Similar Items

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
by: Tássia S. Tavares, et al.
Published: (2020-10-01)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
by: Gehan Botrus, et al.
Published: (2022-10-01)

Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective
by: Fatemeh Mirzayeh Fashami, et al.
Published: (2023-05-01)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
by: Abigale Clark, DO, et al.
Published: (2023-09-01)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01)

Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress
by: Raúl Ortíz, et al.
Published: (2021-04-01)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant <i>Brca1</i> Proficient and Deficient Murine Ovarian Cells
by: Michela Chiappa, et al.
Published: (2022-04-01)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
by: Hongyu Qin, et al.
Published: (2023-01-01)

Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study
by: Hamid Sheikh, et al.
Published: (2023-05-01)

Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
by: Shi Su, et al.
Published: (2020-09-01)

Nanotherapies from an oncologist doctor's view
by: Shuangqing Liu, et al.
Published: (2023-01-01)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
by: Jian Pan, et al.
Published: (2022-09-01)

Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib
by: Tao Zhang, et al.
Published: (2024-02-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Synergistic antitumor efficacy of rMV-Hu191 and Olaparib in pancreatic cancer by generating oxidative DNA damage and ROS-dependent apoptosis
by: Chu-di Zhang, et al.
Published: (2024-01-01)

Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux
by: Ruixue Liu, et al.
Published: (2024-02-01)

Pharmacologic Ascorbate Radiosensitizes Pancreatic Cancer but Radioprotects Normal Tissue: The Role of Oxidative Stress-Induced Lipid Peroxidation
by: Gloria Y. Chen, et al.
Published: (2024-03-01)

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
by: Dominik Dannehl, et al.
Published: (2023-07-01)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
by: Brigida Anna Maiorano, et al.
Published: (2023-04-01)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
by: Jing Ni, et al.
Published: (2019-11-01)

Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
by: Kitti Andreidesz, et al.
Published: (2021-02-01)

Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo
by: Nanami Nakamura, et al.
Published: (2022-02-01)

Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma
by: Arash Navran, et al.
Published: (2024-01-01)

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer
by: Sarah E. Paraghamian, et al.
Published: (2023-12-01)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
by: Ana Beatriz Varanda, et al.
Published: (2020-07-01)

Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks
by: Yuning Jiang, et al.
Published: (2021-10-01)

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
by: Setor Amuzu, et al.
Published: (2021-03-01)

Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer
by: Garett J. Steers, et al.
Published: (2022-05-01)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
by: Laurie Freire Boullosa, et al.
Published: (2023-03-01)

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses
by: Jennifer Moran, et al.
Published: (2023-01-01)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
by: Isabella Faraoni, et al.
Published: (2019-09-01)

UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway
by: Wenjing Hu, et al.
Published: (2021-09-01)

BRCA2‐positive lung adenocarcinoma treated with olaparib: A case report
by: Takumi Motohashi, et al.
Published: (2024-03-01)

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
by: Jin Won Kim, et al.
Published: (2020-02-01)

Olaparib Conjugates with Selenopheno[3,2-<i>c</i>]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance
by: Marina Makrecka-Kuka, et al.
Published: (2022-11-01)

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
by: Danny Feijtel, et al.
Published: (2023-02-01)

Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer
by: Garett J. Steers, et al.
Published: (2023-08-01)

Catalase Modulates the Radio-Sensitization of Pancreatic Cancer Cells by Pharmacological Ascorbate
by: Juan Du, et al.
Published: (2021-04-01)

PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
by: Wen-Jing Hsu, et al.
Published: (2021-10-01)